Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Highlights R&D Productivity Gains In First Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.
Advertisement

Related Content

Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter
Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter
Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure
Putting The Pieces Together Again: GSK Creates End-To-End Business Units
GSK's "Biotech-In-A-Pharma" R&D Model Makes Progress

Topics

Advertisement
UsernamePublicRestriction

Register

PS072159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel